SANOFIPharmaceuticals
Sanofi India Limited — Profit & Loss Statement
₹3209.70
-3.82%
Sanofi India Limited Profit & Loss Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -10.15 Cr | 5.27 Cr | 36.34 Cr | 123.48 Cr | — |
| Tax Rate For Calcs | 0.27 | 0.31 | 0.28 | 0.25 | — |
| Normalized EBITDA | 508.30 Cr | 552.80 Cr | 779.00 Cr | 830.30 Cr | — |
| Total Unusual Items | -37.20 Cr | 17.00 Cr | 128.90 Cr | 495.80 Cr | — |
| Total Unusual Items Excluding Goodwill | -37.20 Cr | 17.00 Cr | 128.90 Cr | 495.80 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 313.70 Cr | 364.60 Cr | 620.60 Cr | 944.40 Cr | — |
| Reconciled Depreciation | 38.20 Cr | 39.60 Cr | 41.90 Cr | 66.70 Cr | — |
| Reconciled Cost Of Revenue | 998.10 Cr | 967.10 Cr | 1.24K Cr | 1.36K Cr | — |
| EBITDA | 471.10 Cr | 569.80 Cr | 907.90 Cr | 1.33K Cr | — |
| EBIT | 432.90 Cr | 530.20 Cr | 866.00 Cr | 1.26K Cr | — |
| Net Interest Income | 11.70 Cr | 41.90 Cr | 57.20 Cr | 61.30 Cr | — |
| Interest Expense | 1.50 Cr | 1.70 Cr | 1.70 Cr | 1.80 Cr | — |
| Interest Income | 13.20 Cr | 43.60 Cr | 58.90 Cr | 63.10 Cr | — |
| Normalized Income | 340.75 Cr | 352.87 Cr | 528.04 Cr | 572.08 Cr | — |
| Net Income From Continuing And Discontinued Operation | 413.30 Cr | 602.90 Cr | 620.60 Cr | 944.40 Cr | — |
| Total Expenses | 1.54K Cr | 1.53K Cr | 2.06K Cr | 2.23K Cr | — |
| Rent Expense Supplemental | 1.70 Cr | 0.70 Cr | 1.70 Cr | 3.60 Cr | — |
| Diluted Average Shares | 2.30 Cr | 2.30 Cr | 2.30 Cr | 2.30 Cr | — |
| Basic Average Shares | 2.30 Cr | 2.30 Cr | 2.30 Cr | 2.30 Cr | — |
| Diluted EPS | 179.46 | 261.78 | 269.47 | 410.06 | — |
| Basic EPS | 179.46 | 261.78 | 269.47 | 410.06 | — |
| Diluted NI Availto Com Stockholders | 413.30 Cr | 602.90 Cr | 620.60 Cr | 944.40 Cr | — |
| Net Income Common Stockholders | 413.30 Cr | 602.90 Cr | 620.60 Cr | 944.40 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 413.30 Cr | 602.90 Cr | 620.60 Cr | 944.40 Cr | — |
| Net Income Including Noncontrolling Interests | 413.30 Cr | 602.90 Cr | 620.60 Cr | 944.40 Cr | — |
| Net Income Discontinuous Operations | 99.60 Cr | 238.30 Cr | — | — | — |
| Net Income Continuous Operations | 313.70 Cr | 364.60 Cr | 620.60 Cr | 944.40 Cr | — |
| Tax Provision | 117.70 Cr | 163.90 Cr | 243.70 Cr | 313.20 Cr | — |
| Pretax Income | 431.40 Cr | 528.50 Cr | 864.30 Cr | 1.26K Cr | — |
| Other Non Operating Income Expenses | 1.00 Cr | 14.70 Cr | 12.40 Cr | 4.20 Cr | — |
| Special Income Charges | -37.20 Cr | 17.00 Cr | 128.90 Cr | 495.80 Cr | — |
| Other Special Charges | -0.50 Cr | -24.70 Cr | -131.80 Cr | -495.80 Cr | — |
| Restructuring And Mergern Acquisition | 37.70 Cr | 7.70 Cr | — | — | — |
| Net Non Operating Interest Income Expense | 11.70 Cr | 41.90 Cr | 57.20 Cr | 61.30 Cr | — |
| Interest Expense Non Operating | 1.50 Cr | 1.70 Cr | 1.70 Cr | 1.80 Cr | — |
| Interest Income Non Operating | 13.20 Cr | 43.60 Cr | 58.90 Cr | 63.10 Cr | — |
| Operating Income | 453.70 Cr | 453.30 Cr | 665.60 Cr | 695.80 Cr | — |
| Operating Expense | 537.20 Cr | 561.20 Cr | 817.90 Cr | 865.20 Cr | — |
| Other Operating Expenses | 121.40 Cr | 112.30 Cr | 166.30 Cr | 152.90 Cr | — |
| Depreciation And Amortization In Income Statement | 36.70 Cr | 36.50 Cr | 41.90 Cr | 66.70 Cr | — |
| Amortization | 0.90 Cr | 0.30 Cr | 1.00 Cr | 24.10 Cr | — |
| Depreciation Income Statement | 35.80 Cr | 36.20 Cr | 40.90 Cr | 42.60 Cr | — |
| Selling General And Administration | 160.70 Cr | 145.00 Cr | 243.10 Cr | 240.10 Cr | — |
| Selling And Marketing Expense | 105.90 Cr | 96.20 Cr | 168.20 Cr | 159.70 Cr | — |
| General And Administrative Expense | 54.80 Cr | 48.80 Cr | 74.90 Cr | 80.40 Cr | — |
| Rent And Landing Fees | 1.70 Cr | 0.70 Cr | 1.70 Cr | 3.60 Cr | — |
| Gross Profit | 990.90 Cr | 1.01K Cr | 1.48K Cr | 1.56K Cr | — |
| Cost Of Revenue | 998.10 Cr | 967.10 Cr | 1.24K Cr | 1.36K Cr | — |
| Total Revenue | 1.99K Cr | 1.98K Cr | 2.73K Cr | 2.92K Cr | — |
| Operating Revenue | 1.99K Cr | 1.98K Cr | 2.73K Cr | 2.92K Cr | — |
| Write Off | — | — | 2.90 Cr | 0.00 | 41.70 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sanofi India Limited
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.